1Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection [ J ]. Clin Microbiol Rev, 2012,25 ( 1 ) : 142-163.
2Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences [ J ]. N Engl J Med,2004,350 ( 11 ) : 1118-1129.
3World Health OrganizaiorL Hepatitis B ( Revised August 2008 ) [ EB/ OL]. [ 2010-12-9 ]. http://www, who. int/mediacentre/factsheets / fs204/en/.
4Giles M, Visvanathan K, Sasadeusz J. Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding [ J ]. Antivir Ther, 2011, 16:621-628.
5Sonneveld M J, Janssen HL. Chronic hepatitis B:pegintefferon or nucleos (t) ide analogues? [J]. Liver Int,2011,31 Suppl 1:78-84.
6Apostolova N, Blas-Garcia A, Esplugues JV. MitochondnaI toxicity m HAART: an overview of in vitro evidence[ J ]. Curt Pharm Des ,2011,17 (20) :2130-2144.
7Kim BK,Oh l, Kwon SY, et ak Clevudine myopathy in patiems with chronic hepatitis B[J]. J Hepatol,2009,51 (4) : 829-834.
8Lin CC, Xu C, Teng A, et al. Pharmacokinetics of pradefovir and PMEA in Healthy Volunteers After Oral Dosing of pradefovir [ J]. J Clin Pharmaco1,2005,45 ( 11 ) : 1250-1258.
9Hynieka LM, Yunker N, Patel PH. A Review of Oral Antiretroviral Therapy for the Treatment of Chronic Hepatitis B [ J ]. Ann Pharmacother,2010 ,'14 ( 7-8 ) :1271-1286.
10Lin CC, Fang C, Benetton S, et al. Metabolic Activating of pradefovir by CYP3A4 and Its Potential as an Inhibitor or Inducer[ J]. Antimicrob Agents Chemother,2006,50(9) :2926-2931.
